China SXT Pharmaceuticals, Inc. Class A Ordinary Shares

SXTCRank #122
$0.1112+75.39% 1D
$0.061952-week range$83,758.4

Updated . Prices are snapshots and may be delayed.

China SXT Pharmaceuticals, Inc. Class A Ordinary Shares price chart

+58.57% over 7D
$0.111
$0.062
Oct 18
Oct 20

AI Outlook for China SXT Pharmaceuticals, Inc. Class A Ordinary Shares

Bearish posture
  • Long-term trend
    -100.0% vs 200-day average
  • Medium-term trend
    -95.5% vs 50-day average
  • Averages
    50-day below 200-day
  • 3 more trend and momentum checks
  • Nearby support and resistance levels
  • What would strengthen or weaken the picture

Posture describes where the price stands today, from its own trend and momentum. It is not a forecast, a price target or financial advice. How it is worked out

China SXT Pharmaceuticals, Inc. Class A Ordinary Shares performance

1D
+75.4%
7D
+8.8%
30D
−95.4%
90D
−99.9%
1Y
−100.0%

About China SXT Pharmaceuticals, Inc. Class A Ordinary Shares

China SXT Pharmaceuticals, Inc. Class A Ordinary Shares is a pharmaceuticals company based in China, listed on NASDAQ since 2019 (ticker SXTC).

Its market capitalisation is $0 million, the #122 largest of the 122 stocks Air Radar has market-cap data for.

China SXT Pharmaceuticals, Inc. Class A Ordinary Shares market data

What is the price of China SXT Pharmaceuticals, Inc. Class A Ordinary Shares today?

China SXT Pharmaceuticals, Inc. Class A Ordinary Shares (SXTC) is at $0.1112, +75.39% on the day.

What is the 52-week range of China SXT Pharmaceuticals, Inc. Class A Ordinary Shares?

Over the past year China SXT Pharmaceuticals, Inc. Class A Ordinary Shares has traded between $0.0619 and $83,758.4. It is currently 0% of the way up that range.

What is the market cap of China SXT Pharmaceuticals, Inc. Class A Ordinary Shares?

China SXT Pharmaceuticals, Inc. Class A Ordinary Shares has a market capitalisation of $102,278, the #122 largest of the stocks Air Radar has market-cap data for.

Similar stocks

Prices are snapshots from market data providers and may be delayed. This page is for information only and is not investment advice.